Antisense Oligonucleotide Therapy for Neurodevelopmental Disorders
Developmental Neuroscience · 2021 · 43 (3-4) · 247-252
DOI: 10.1159/000517686 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Developmental Neuroscience, online erschienen am 05.08.2021. Verfasst von Sophie F Hill und 1 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience Graduate Program, University of Michigan, Ann Arbor, Michigan, USA. Hauptthemen laut MEDLINE: Muscular Atrophy, Spinal, Neurodevelopmental Disorders. Die Arbeit wurde bisher 86-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS.
Abstract (Originalsprache)
Antisense oligonucleotides (ASOs) are short oligonucleotides that can modify gene expression and mRNA splicing in the nervous system. The FDA has approved ASOs for treatment of ten genetic disorders, with many applications currently in the pipeline. We describe the molecular mechanisms of ASO treatment for four neurodevelopmental and neuromuscular disorders. The ASO nusinersen is a general treatment for mutations of SMN1 in spinal muscular atrophy that corrects the splicing defect in the SMN2 gene. Milasen is a patient-specific ASO that rescues splicing of CNL7 in Batten’s disease. STK-001 is an ASO that increases expression of the sodium channel gene SCN1A by exclusion of a poison exon. An ASO that reduces the abundance of the SCN8A mRNA is therapeutic in mouse models of developmental and epileptic encephalopathy. These examples demonstrate the variety of mechanisms and range of applications of ASOs for treatment of neurodevelopmental disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Neuroscience Graduate Program, University of Michigan, Ann Arbor, Michigan, USA.
- Department of Human Genetics, University of Michigan, Ann Arbor, Michigan, USA.
Förderung
- NINDS NIH HHS
Zitieren
APA
Hill, S. F., & Meisler, M. H. (2021). Antisense Oligonucleotide Therapy for Neurodevelopmental Disorders. Developmental Neuroscience, 43(3-4), 247-252. https://doi.org/10.1159/000517686
Vancouver
Hill SF, Meisler MH. Antisense Oligonucleotide Therapy for Neurodevelopmental Disorders. Developmental Neuroscience. 2021;43(3-4):247-252. doi:10.1159/000517686
BibTeX
@article{Hill2021,
author = {Hill, Sophie F and Meisler, Miriam H},
title = {Antisense Oligonucleotide Therapy for Neurodevelopmental Disorders},
journal = {Developmental Neuroscience},
year = {2021},
volume = {43},
number = {3-4},
pages = {247--252},
doi = {10.1159/000517686}
}
EUVIMED